---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-012372"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T09:48:43.877552+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# X4 Pharma reports FY2023 net loss $101.2M; cash $115.2M; PDUFA for WHIM syndrome April 30

## Summary
- Net loss $19.1M Q4 and $101.2M FY2023; R&D $15.3M Q4 and $72.0M FY2023; SG&A $9.9M Q4 and $35.5M FY2023.
- Cash, equivalents, restricted cash and marketable securities of $115.2M at Dec 31, 2023; runway into 2025.
- FDA PDUFA target action date April 30, 2024 for mavorixafor in WHIM syndrome; launch preparations underway.
- Additional Phase 2 results and global Phase 3 trial initiation for chronic neutropenia expected in 1H24.
- No guidance change; projected runway excludes debt drawdowns or potential Priority Review Voucher monetization.

## SEC filing metadata
- accession: 0001628280-24-012372
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828024012372/0001628280-24-012372-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828024012372/xfor-20240321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-012372
- JSON: https://secwatch.observer/filing/0001628280-24-012372.json
- Plain text: https://secwatch.observer/filing/0001628280-24-012372.txt

## Key facts
- Earnings Releases
  X4 Pharmaceuticals, Inc reported the full year ended December 31, 2023 results: net income net loss of $101.2 million.
  - Period: the full year ended December 31, 2023
  - Net income: net loss of $101.2 million
  - Result: reported results
  source text: X4 reported a net loss of $19.1 million and $101.2 million for the fourth quarter and full year ended December 31, 2023, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501697/000162828024012372/0001628280-24-012372-index.htm
- Earnings Releases
  X4 Pharmaceuticals, Inc reported the fourth quarter ended December 31, 2023 results: net income net loss of $19.1 million.
  - Period: the fourth quarter ended December 31, 2023
  - Net income: net loss of $19.1 million
  - Result: reported results
  source text: X4 reported a net loss of $19.1 million and $101.2 million for the fourth quarter and full year ended December 31, 2023, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501697/000162828024012372/0001628280-24-012372-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.